New literature on interstitial cystitis and relevant subjects
click on the title to jump to the abstract
nonbladder syndromes
Antecedent nonbladder syndromes in case-control study of interstitial cystitis/painful bladder syndrome. Warren JW, Howard FM, Cross RK, et al. Urology 2008 November 7. [Epub ahead of print] PMID:18995888
• seeking clues to the pathogenesis of IC/PBS, these researchers sought antecedent nonbladder syndromes that distinguished incident IC/PBS from matched controls
• eleven antecedent syndromes were more often diagnosed in those with IC/PBS, and most syndromes appeared in clusters
• among the hypotheses generated was that some patients with IC/PBS have a systemic syndrome and not one confined to the bladder
diet
Diététique et cystite interstitielle. Saussine C. Mouracade P. Pelv Perineol 2008;3:50-52
Article in French. English abstract.
- the role of diet as an aggravating factor of interstitial cystitis (IC) symptoms is increasingly acknowledged
- many IC patients note that some foods worsen their symptoms and that diet modification may relieve symptoms
- however, the same foods do not aggravate symptoms in all patients
- some patients have found that diet has no effect
ESSIC criteria
Utilisation des nouveaux critères diagnostiques de la cystite interstitielle dans la pratique quotidienne: à propos de 156 cas. [Using the interstitial cystitis new diagnostic criteria in daily practice: about 156 patients]. Mouracade P, Lang H, Jacqmin D, Saussine C. Progrès en Urologie 2008;18:674-7. Epub 2008 Jul 1. Article in French, abstract in English. PMID: 18971112. • P. Mouracade and colleagues from France found that 26% (41 patients) of 156 patients (all diagnosed with IC and all with pain) were excluded by the ESSIC 2005 definition (which like the ICS 2002 definition specified ”suprapubic pain”) • when applying the most recent ESSIC definition (“Chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder…”), 15% (23) of these 41 patients were re-integrated. However this still left 11% excluded
fibromyalgia
A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Uçeyler N, Häuser W, Sommer C. Arthritis Rheum 2008;59:1279-98
• in this systematic review it is concluded that amitriptyline (25-50 mg/day) reduced pain, fatigue, and depressiveness in patients with fibromyalgia and improved sleep and quality of life • most SSRIs and the SNRIs duloxetine and milnacipran are probably also effective
• the authors recommend short-term treatment of patients with fibromyalgia using amitriptyline or another of the antidepressants that were effective in randomized-controlled trials but warn that data on long-term efficacy are lacking
depression and abuse
Depression, abuse and its relationship to interstitial cystitis. Goldstein HB, Safaeian P, Garrod K, et al. Int Urogynecol J Pelvic Floor Dysfunct 2008 Sep 3. [Epub ahead of print].
• the prevalence of childhood sexual abuse in the sample was not significantly different than the US average.
• the prevalence of physical abuse in the sample was not statistically different than the US average.
pelvic pain model
Summation model of pelvic pain in interstitial cystitis. Klimpp DJ, Rudick CN. Nat Clin Pract Urol 2008;5:494-500
• suggests that pelvic organ crosstalk might modulate symptoms of pelvic pain by spatial and temporal summation, suggesting a mechanism for the benefits of dietary modification in patients with IC, as well as therapeutic opportunities
cytokines
Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Saini R, Gonzalez RR, Te AE. Curr Urol Rep 2008;9:314-9 • this paper reviews the role of cytokines in the pathophysiology of chronic prostatitis/chronic pelvic pain syndrome, overactive bladder, and painful bladder syndrome/interstitial cystitis • cytokines may play a role by recruiting inflammatory cells and ultimately in inducing symptoms
Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Nordling J, van Ophoven A. Arzneimittelforschung 2008;58:328-35 .(PMID:18751498)
• effectiveness, safety nd tolerability of instillation therapy with chondroitin sulphate was investigated in 286 patients with chronic forms of cystitis including radiation cystitis, overactive bladder, chronically recurring cystitis and IC.
• the instillation was effective and well tolerated in the treatment of chronic forms of cystitis associated with a possible GAG layer deficit, but the results need to be confirmed in a controlled study.
intravesical chondroitin sulphate
A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. Nickel JC, Egerdie B, Downey J, et al. BJU Int 2008 Sep 3. [Epub ahead of print] • a multicentre, community based open-label study designed to assess the efficacy and safety of intravesical sodium chondroitin sulphate in the treatment of patients with the clinical diagnosis of interstitial cystitis (IC)
• patients with IC were treated with sodium chondroitin sulphate (Uracyst®) solution 2.0% via urinary catheter weekly for 6 weeks and then monthly for 16 weeks for a total of 10 treatments
• the primary endpoint was the percentage of responders to treatment as indicated by a marked or moderate improvement on a seven-point patient Global Response Assessment (GRA) scale at week 10 (4 weeks after the initial six treatments) compared with baseline; a secondary efficacy endpoint (durability) was the percentage of responders on the GRA scale after 10 treatments.
• 47% of the 53 enrolled patients with long standing moderately severe IC were responders at week 10; at 24 weeks, 60% were responders
Hunner's ulcer
The role of cystoscopy in the diagnosis of Hunner's ulcer disease. Braunstein R, Shapiro E, Kaye J, Moldwin R. J Urol 2008 Aug 14. [Epub ahead of print] PMID: 18707698 • according to the authors, their data from this study demonstrate that standard clinical evaluation cannot reliably distinguish Hunner's ulcer IC from non-Hunner's ulcer IC
• these findings suggest that cystoscopy is necessary to accurately identify patients with Hunner's ulcer
pain sites
Sites of pain from interstitial cystitis/painful bladder syndrome. Warren JW, Langenberg P, Greenberg P, et al. J Urol 2008 Aug 14. [Epub ahead of print] PMID: 18707715
• multiple pain sites are common in IC/PBS
• in this study the authors hypothesized that careful and systematic description might provide clues to its pathogenesis
• they concluded that suprapubic prominence and changes in the voiding cycle are features consistent with but do not prove that the bladder is the pain generator in IC/PBS and the pain sites described by patients are referred from it
Fibromyalgia syndrome: a relevant recent construction of an ancient condition? Perrot S. Curr Opin Support Palliat Care 2008;2:122-7
• this review asks: Is fibromyalgia a rheumatic condition related to neurological dysfunction?
• studies of neuropathic pain suggest that fibromyalgia probably results from abnormal central pain processing rather than a musculoskeletal abnormality • fibromyalgia syndrome may may represent a common clinical presentation of various pathophysiological disorders • future studies may identify subgroups related to different pathophysiological mechanisms, thereby leading not only to the development of more specific curative but also preemptive treatments
Deep dyspareunia: causes, treatments, and results. Ferrero S, Ragni N, Remorgida V. Curr Opin Obstet Gynecol 2008;20:394-9 • endometriosis, pelvic congestion syndrome, and interstitial cystitis have been associated with deep dyspareunia • treatment of deep dyspareunia should be mainly directed to causative factors; however, clinicians should keep in mind that secondary sexual dysfunction can arise from organic pelvic pathology
a review article in French
La cystite interstitielle en 2008. Mouracade P, Saussine C. Prog Urol 2008 Jul;18(7):418-25. Epub 2008 May 27. PMID: 18602600 •a review article in French •la CI reste une pathologie meconnue par le monde medical et le grand public •la reconnaissance de la physiopathologie rend les traitements encore empiriques
Prevalence and psychosocial correlates of symptoms suggestive of painful bladder syndrome: results from the Boston Area Community Health Survey. Link CL, Pulliam SJ, Hanno PM, et al. J Urol. 2008 Jun 11. [Epub ahead of print] •the overall prevalence of symptoms suggestive of painful bladder syndrome was 2% (1.3% in men and 2.6% in women) with increased prevalence in middle-aged adults and those of lower socioeconomic status • symptoms suggestive of painful bladder syndrome were more common in those who experienced abuse, in those who were worried about someone close to them and in those who were having trouble paying for basics; this pattern held even after adjusting for depression. • the authors conclude that painful bladder syndrome is associated with a number of lifestyle and psychosocial correlates, suggesting that the treatment may benefit from a multifaceted approach of combining medical, psychological and cognitive treatment.
resiniferatoxin
Resiniferatoxin in the treatment of interstitial cystitis: a systematic review. Mourtzoukou EG, Iavazzo C, Falagas ME. Int Urogynecol J Pelvic Floor Dysfunct 2008 Jun 19 [Epub ahead of print]
• in this review from Greece, the authors conclude that the effectiveness of resiniferatoxin in the treatment of interstitial cystitis remains unknown; six studies produced contradictory results
Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Warren JW, Brown V, Jacobs S, et al. Urology 2008;71:1085-90 • the retrospective data in this study suggest that a proportion, probably a minority, of women at IC/PBS onset had evidence of UTI or inflammation • the results indicate that UTI is present at the onset of IC/PBS in some women and might reveal clues to IC/PBS pathogenesis
review
What is new in bladder pain syndrome/interstitial cystitis? Hanno P, Nordling J, van Ophoven A. Curr Opin Urol 2008;18:353-8
• in this review the authors bring practicing healthcare providers up to date with the literature on bladder pain syndrome/interstitial cystitis, and the implications for their patients
Mast cell-derived histamine mediates cystitis pain.(click on the title for full article) Rudick CN, Bryce PJ, Guichelaar LA, et al. PLos ONE 2008 May 7;3(5):e2096
• data obtained from this study demonstrate that mast cells promote cystitis pain and bladder pathophysiology through the separable actions of histamine and tumor necrosis factor alpha (TNF), respectively
• the authors conclude that pain is independent of pathology and inflammation, and histamine receptors represent direct therapeutic targets for pain in IC and other chronic pain conditions
cyclosporine A
Cyclosporine A in the Treatment of Interstitial
Cystitis. Jukka Sairanen. Academic dissertation, University of Helsinki, Finland, 25 January 2008 • the author concludes that cyclosporin A is a viable treatment option in patients with PBS/IC who fulfil the
NIDDK criteria and have serious symptoms and in whom previous attempts to alleviate
symptoms have failed; the author also concludes that his results support the need for future clinical studies with drug
compounds that modulate inflammation in PBS/IC bladder.
depression and anxiety
Psychological profile of Taiwanese interstitial cystitis patients. Fan YH, Lin AT, Wu HM, et al. Int J Urol 2008;15:416-8 PMID: 18452458
• the researchers found that most of their Taiwanese patients had significant depression and anxiety and that the extent of the symptoms appeared to correlate with the severity of the IC symptoms
Treatment of Bladder Pain Syndrome/Interstitial Cystitis 2008: Can we make evidence-based decisions? Fall M, Oberpenning F, Peeker R. Eur Urol 2008 Apr 3 [Epub ahead of print] PMID: 18403099
• a review of treatment; controlled studies are scarce; much evidence is based on a trial and error principle and studies give conflicting results
• everyone has their own different perceptions as to what interstitial cystitis and painful bladder syndrome are and how they should be treated
• it is described by the authors as a poorly defined heterogeneous spectrum of disorders
• inclusion and exclusion criteria in studies form a significant problem; definitions are loose and differ from centre to centre and in different parts of the world
care
Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome. Peters KM, Carrico DJ, Diokno AC. Urology 2008;71:634-40 • the described population of women with unrelieved chronic pain, frequency, and urgency is in desperate need of care.
• the authors conclude that it may be most therapeutic to develop a multimodal plan of care that includes physical therapy, oral and intravesical therapies, neuromodulation, and cognitive-behavioral therapies
pain
Evidence-based criteria for pain of
interstitial cystitis/painful bladder syndrome in women. Warren JW, Brown J, Tracy JK, et al. Urology 2008;71:444-8
• in this Events Preceding Interstitial Cystitis study, pain that worsened with a certain food or
drink and/or worsened with bladder filling and/or improved with urination was reported by 151(97%) of 156 patients; these were the only three criteria that applied directly to the bladder
• the same three criteria described the pain of 262 (97%) of 270 women in the Interstitial Cystitis
Database who “definitely” had IC/PBS • the authors conclude that this triad might
describe the pain of IC/PBS and contribute to a sensitive case definition
Longidaze in therapy of patients with interstitial cystitis[Article in Russian] Zaitcev AV, Pushkar DU. Urologiia 2007 Sept-Oct;(5):35-7 • a pilot study using the injected enzyme agent longidaze (conjugate of hyaluronidase with activated derivate of N-oxide poly-1,4-ethylenpiperazine) in a study group of 30 patients (including 7 Hunner's ulcer/lesion patients): 3000 IU, 10 injections, every 5 days
• the authors believe that the algorithm for Hunner's patients should include Holmium laser coagulation as a first step, followed by longidaze treatment
• in non-ulcerative patients the longidaze is added to multimodal treatment
• the aim of the therapy is to correct inflammatory disorders, prevent progressive fibrosis, and restore detrusor elasticity
• the results of this pilot study were positive and the study will be continued
botulinum A toxin
Botulinum A Toxin Intravesical Injection in Patients With Painful Bladder Syndrome: 1-Year Followup.
Giannantoni A, Porena M, Costantini E, et al. J Urol 2008 Jan 17 [Epub ahead of print]
• in this small study, intravesically injected botulinum toxin A appeared to be effective for short-term treatment of PBS that has failed to respond to other treatment
• this form of treatment needs to be repeated after a few months
RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model. Liu W, Deyoung BR, Chen X, et al. J Autoimmun. 2007 Dec 24 [Epub ahead of print]
• RDP58 is a novel d-amino acid decapeptide with potent immunosuppressive activity
• this study investigated whether it was effective as an intravesical agent for treating bladder autoimmune inflammation in mouse model
• collectively the results indicated that RDP58 is effective for treating T cell-mediated experimental autoimmune cystitis and may serve as a useful intravesical agent for the treatment of autoimmune-associated bladder inflammation such as IC.
hyaluronate
Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Riedl CR, Engelhardt PF, Daha KL, et al. Int Urogynecol J Pelvic Floor Dysfunct 2007 Dec 21 [Epub ahead of print] • this study evaluated the efficacy of intravesical hyaluronan therapy in 126 patients with IC/PBS and mean disease duration of 6.1 years; to be eligible for hyaluronan treatment, a positive modified potassium test was requested as a sign of a urine-tissue barrier disorder • patients were treated with weekly instillations of a 50 ml phosphate-buffered saline solution containing 40 mg sodium hyaluronate
• data were obtained by a visual analogue scale (VAS) questionnaire rating from 0 to 10 that asked for global bladder symptoms before and after therapy; additional questions evaluated the therapeutic impact on quality of life
• 85% of the patients reported symptom improvement (2 or more VAS units); the mean initial VAS score of 8.5 decreased to 3.5 after therapy (p<0.0001); 55% remained with no or minimal bladder symptoms after therapy (VAS 0-2); 84% reported significant improvement of their quality of life
• intravesical therapy had to be initiated again with good success in 43 patients (34.5%) as symptoms recurred after discontinuation of treatment, while the rest stayed free of symptoms for up to 5 years
• in general, hyaluronan therapy was well tolerated and, with the exception of mild irritative symptoms, no adverse reactions were reported for a total of 1,521 instillations
• the authors conclude that timely hyaluronan instillation therapy may lead to complete symptom remission or even cure in part of the IC/PBS patients, while some responders need continuous intravesical therapy
• the present results suggest that selection of patients for hyaluronan therapy by potassium testing improves the outcome of intravesical therapy with a response rate of >80%
Re-imagining Interstitial Cystitis. Hanno PM. Urol Clin North Am 2008;35:91-9 • a review of the history of changes and developments in IC and PBS down to the present day controversies
management review
Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. Dimitrakov J, Kroenke K, Steer WD, et al. Arch Intern Med 2007;167:1922-9 • over 180 different therapies have been tried for PBS/IC, yet evidence from trials remains inconclusive
• this study concludes that PPS may be modestly beneficial for PBS/IC
• there is insufficient evidence for other pharmacologic treatment
• a consensus on standardized outcome measures is urgently needed